Latest News
London pre-open: FTSE set to dip as property wobble continues
The FTSE 100 is expected to move around 13 points lower on Wednesday morning as sterling set a new 31-year low in the early hours of the morning following warnings around Brexit risks from the Bank of England and a new wobble for the property sector.
EasyJet traffic flies higher, Melrose to buy Nortek
London open The FTSE 100 is predicted to dip by around 15 points on Wednesday morning, after its rise to 6,545. 37 on Tuesday.
Wednesday newspaper round-up: Sterling, ITV, BT, Ofcom, Network Rail
The pound plumbed new depths against the dollar and investors rushed for the perceived havens of gold and government bonds as financial turmoil intensified in the wake of the UK’s Brexit vote, with sterling hitting $1. 2798 in early Asian trading on Wednesday — its lowest in more than 31 years. Investors, spooked by a number of UK property funds halting redemptions, switched to risk-off mode and sent yields on government bonds tumbling to new lows. - Financial Times .
Request for international administrative assistance in tax matters
UBS (NYSE:UBS) (SWX:UBSN) has received a disclosure order from the Swiss Federal Tax Administration ("FTA") to transfer information based on a French request for international administrative assistance in tax matters. The request concerns a number of UBS account numbers pertaining to current and former French domiciled clients and is based on data from 2006 and 2008. Since then, the client base underlying the data has changed significantly and a large number of the accounts affected by the French request are closed.
Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM)
Novartis International AG / Novartis PKC412 (midostaurin) pivotal data published in NEJM show 60% response rate in advanced systemic mastocytosis (SM) . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin
Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin Novartis International AG / Largest global psoriasis survey shows 84% of people face discrimination and humiliation because of their skin . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Global survey of over 8,300 people with moderate-to-severe psoriasis is the first to look at perceptions of clear skin[1]Nearly half (45%) have been asked if they are contagious while 55% do not believe clear or almost clear skin is a realistic goal[1]Leading experts call for psoriasis patients to accept nothing less than clear skin - more information available on www.
Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor
Novartis International AG / Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline.
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology
Novartis International AG / Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) [1].
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment
Novartis International AG / Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement. Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation.
Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder
Novartis International AG / Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.